Medtronic has received CE mark for its HVAD System left ventricular assist device (LVAD) for less-invasive implant procedures in patients with advanced heart failure.

The HVAD system uses a smaller incision which reduces surgical bleeding and related blood transfusions, potentially reducing the development of right heart failure consequently minimising the duration of hospital stays.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The thoracotomy implantation technique can keep the area around the heart largely intact and preserve the sternum for future procedures or a heart transplant.

"CE Mark for the thoracotomy procedure is a testament to the HVAD System's flexibility and versatility, and may enable more patients to receive the life-sustaining benefit of the device for the treatment of advanced heart failure."

Medtronic cardiac rhythm and heart failure division medical director and heart failure business vice-president and general manager David Steinhaus said: "The HVAD System is the only full-support, centrifugal LVAD approved in Europe for thoracotomy implantation, providing clinicians with greater freedom to choose the best surgical technique for each patient.

"CE Mark for the thoracotomy procedure is a testament to the HVAD System's flexibility and versatility, and may enable more patients to receive the life-sustaining benefit of the device for the treatment of advanced heart failure."

See Also:

The HVAD System features the small-sized, full-support, centrifugal circulatory assist device, the HVAD Pump which can be easily implanted through a small, lateral thoracotomy incision between a patient's ribs on the left side of the chest.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Currently the prospective LATERAL clinical trial study of a full-support ventricular assist device (VAD) to evaluate this implant technique is being conducted in Canada and the US, where the implant procedure currently is not approved.

The study involved patients with end-stage heart failure who are not responsive to standard medical management and who are eligible for heart transplantation.